InvestorsHub Logo
Followers 19
Posts 4568
Boards Moderated 0
Alias Born 04/12/2017

Re: None

Tuesday, 01/24/2023 10:06:30 AM

Tuesday, January 24, 2023 10:06:30 AM

Post# of 463730
Not impressed, with this non placebo controlled trial.

Imagine if we had this data? We would be in penny land!

ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.

47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 points. An additional 23% of patients declined less than 5 points on ADAS-Cog over 1 year, and this group declined by 2.5 points.

Mild patients responded better than patients with moderate Alzheimer’s disease.

Simufilam was safe, well tolerated.



https://finance.yahoo.com/news/cassava-sciences-announces-positive-top-141500143.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News